A phase 2b randomized trial of Visugromab

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2024 According to a CatalYm media release, the company based on the results from the ongoing GDFATHER Phase 1/2a trial, CatalYm is currently preparing for a broad Phase 2b program in earlier treatment settings for non-squamous NSCLC and additional tumor indications.
18 Jul 2024 New trial record
16 Jul 2024 According to a CatalYm media release, the company announced completion of a $150 million Series D financing, proceeds from this will be used to the expansion of the company's broad Phase 2b development of visugromab into randomized Phase 2b studies in select checkpoint naive frontline and second-line treatment settings in the first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com